Vanguard Personalized Indexing Management LLC buys 4,340 shares of Fresenius Medical Care AG (NYSE:FMS)

Vanguard Personalized Indexing Management LLC boosted its holdings in Fresenius Medical Care AG (NYSE:FMS – Free Report) by 17.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,680 shares of the company’s stock after purchasing an additional 4,340 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Fresenius Medical Care were worth $548,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the company. Wulff Hansen & CO. raised its stake in shares of Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO now owns 343,429 shares of the company’s stock valued at $6,556,000 after acquiring an additional 325,439 shares in the last quarter. Triasima Portfolio Management inc. purchased a new position in Fresenius Medical Care in the first quarter valued at $1,293,000. Corient Private Wealth LLC boosted its holdings in Fresenius Medical Care by 164.6% in the fourth quarter. Corient Private Wealth LLC now owns 66,134 shares of the company’s stock worth $1,378,000 after purchasing an additional 41,139 shares in the last quarter. Veracity Capital LLC grew its stake in Fresenius Medical Care by 172.2% in the first quarter. Veracity Capital LLC now owns 53,023 shares of the company’s stock worth $1,022,000 after purchasing an additional 33,543 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC bought a new position in shares of Fresenius Medical Care in the first quarter valued at $584,000. 8.25% of the shares are held by hedge funds and other institutional investors.

Fresenius Medical Care price performance

FMS opened at $21.15 on Friday. The company’s 50-day simple moving average is $19.62, and its two-hundred-day simple moving average is $19.93. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.09, and a current ratio of 1.46. The stock has a market cap of $12.41 billion, a P/E ratio of 23.78, a P/E/G ratio of 1.08 and a beta of 0.90. Fresenius Medical Care AG has a 52-week low of $16.37 and a 52-week high of $22.76.

Fresenius Medical Care (NYSE:FMS – Get Free Report ) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.38. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. The company had revenue of $5.13 billion for the quarter, compared to the consensus estimate of $5.28 billion. As a group, analysts predict that Fresenius Medical Care AG will post 1.51 EPS for the current year.

Changes in Analyst Ratings

Several brokerages have recently commented on FMS. Truist Financial decreased their price objective on shares of Fresenius Medical Care from $24.00 to $22.00 and set a “hold” rating on the stock in a research report on Wednesday, July 31st. StockNews.com began coverage on shares of Fresenius Medical Care in a report on Sunday, September 22nd. They issued a “strong buy” rating on the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $22.00, according to MarketBeat.

Check out the latest Fresenius Medical Care stock analysis

About Fresenius Medical Care

(Free Report)

Fresenius Medical Care AG provides dialysis and related services for people with kidney disease in Germany, North America and internationally. The Company provides dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services including clinical monitoring, follow-up care, and arranging for supplies to be delivered to the patient’s residence; and dialysis services under contract with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients suffering from acute renal failure.

Recommended articles

Get Fresenius Medical Care news and reviews daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Fresenius Medical Care and related companies with MarketBeat.com ‘s FREE daily email newsletter.